At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 50 enrolled
Drug / intervention
Spesolimapdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Phase I Trial to Assess Pharmacokinetics and Safety of Single Subcutaneous Doses and Single Intravenous Doses of BI 655130 in Healthy Chinese Male and Female Subjects (Single Doses, Open-label Study in Parallel-group Design).
In Brief
A Phase 1 clinical trial evaluating Spesolimap for Healthy. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The primary objective of this trial is to investigate pharmacokinetics, including dose proportionality, following single intravenous and subcutaneous doses of spesolimab in healthy Chinese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartMay 2020
Primary CompletionApr 2021
Study CompletionJun 2021
TodayJul 2026
First PostedMay 15, 2020
Enrollment StartMay 21, 2020
Primary CompletionApr 7, 2021
Study CompletionJun 4, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.1 years ago
Interventions
Spesolimapdrug
Spesolimap